About GeneGo
GeneGo is a Healthcare company based in San Diego (United States) founded in 2000, and was acquired by Thomson Reuters in November 2010. It operates in the Healthcare and Technology sectors. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Genome Informatics and Integrative Bioinformatics Platforms. Its legal entity is GENEGO, INC. Its competitors include Human Longevity, Helix and Benchling; 3 of its 3 listed competitors have raised funding.
Company details
GeneGo provides biology and disease information, analytics, and decision support solutions for pharmaceutical research and development. It offers MetaBase, a database for systems biology. MetaBase is the knowledge base behind the platform that includes MetaCore and MetaDrug, and is delivered as an Oracle database with more than 200 tables; Meta Miner - oncology platform; MetaDiscovery - platform whcih allows integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks; MetaCore 6.2 - sollution to assist pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology; MetaDrug 6.2 - a solution designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. It also offers analytics, data management, and value-added services. It assists in biomarker discovery patient stratification, target identification, drug resistance and sensitivity, drug repositioning, drug combination discovery, and pharmacology and toxicity assessmentIt was acquired by Thomson Reuters in Nov 2010 and became a part of Healthcare Science business of Thomson Reuters.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website genego.com
- Acquired by Thomson Reuters (Nov 2010)
- Legal Name Genego, Inc
- Latest Funding Round$119.17K (USD), Grant
Sep 2010
- InvestorsThomson Reuters
& 2 more
- Acquired byThomson Reuters
(Nov 2010)
Funding Insights of GeneGo
- Total Rounds 6
- Last Round Grant — $119,166
- First Round $200,000
(May 2008)
- Investors Count 2
All 6 funding rounds of GeneGo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in GeneGo
GeneGo has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Thomson Reuters, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cloud-based legal management and data services are provided for businesses. | 2008 | thomsonreuters.com | Toronto, Canada |
Investor details for GeneGo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of GeneGo
4 dated milestones of GeneGo across 10 years, from founding to its latest funding, stage changes and deals.
- Founded GeneGo is founded.
- Funding First funding round of $200K.
- Funding Latest funding round, Grant, of $119K.
- Exit Acquired by Thomson Reuters.
Competitors of GeneGo
GeneGo has 3 listed competitors in our database, 3 of them funded. They include Human Longevity, Helix and Benchling.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humanlongevity.com | 2013 | San Diego, United States | $376.72M | 83 | Genomics data and cell therapy-based diagnostic and therapeutic solutions | |
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. |
Detailed competitors of GeneGo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GeneGo
Websites that share an audience with GeneGo (genego.com).
Websites whose visitors overlap most with GeneGo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ingenuity.com | 100% | 24.3K | #619,156 | View details | |
| thehamner.org | 88% | View details | |||
| lhasalimited.org | 88% | 12.2K | #1,940,895 | View details | |
| genedata.com | 88% | 36.5K | #383,117 | View details | |
| invitrogen.com | 88% | 5.2K | #3,688,642 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for GeneGo
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GeneGo (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GeneGo
GeneGo was founded in 2000 and raised its 1st funding round 8 years after it was founded.
GeneGo is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
GeneGo provides biology and disease information, analytics, and decision support solutions for pharmaceutical research and development. It offers MetaBase, a database for systems biology. MetaBase is the knowledge base behind the platform that includes MetaCore and MetaDrug, and is delivered as an Oracle database with more than 200 tables; Meta Miner - oncology platform; MetaDiscovery - platform whcih allows integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks; MetaCore 6.2 - sollution to assist pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology; MetaDrug 6.2 - a solution designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. It also offers analytics, data management, and value-added services. It assists in biomarker discovery patient stratification, target identification, drug resistance and sensitivity, drug repositioning, drug combination discovery, and pharmacology and toxicity assessmentIt was acquired by Thomson Reuters in Nov 2010 and became a part of Healthcare Science business of Thomson Reuters.
GeneGo's top competitors include Helix, Human Longevity and Benchling.
GeneGo has 3 investors. Key investors include Thomson Reuters, HHS, and National Cancer Institute.
GeneGo operates through Genego, Inc.
Yes. GeneGo was acquired by Thomson Reuters in November 2010.